In the low-risk group, immune-related pathways were enriched as expected, including the T cell receptor signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, NF-κB signaling pathway, and NK cell-mediated cytotoxicity. The gene discussed is NFKB1; the disease is cancer.